SB-228357
Identifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H17F4N3O2 |
Molar mass | 431.391 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
SB-228357 is a drug which acts as an antagonist for the 5HT2B and 5HT2C receptors. It has antidepressant and anxiolytic effects in animal models,[1][2] and inhibits 5-HT2B mediated proliferation of cardiac fibroblasts.[3]
See also
References
- ↑ Reavill C, Kettle A, Holland V, Riley G, Blackburn TP (February 1999). "Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist". British Journal of Pharmacology. 126 (3): 572–4. doi:10.1038/sj.bjp.0702350. PMC 1565856. PMID 10188965.
- ↑ Bromidge SM, Dabbs S, Davies DT, Davies S, Duckworth DM, Forbes IT, et al. (March 2000). "Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent". Journal of Medicinal Chemistry. 43 (6): 1123–34. doi:10.1021/jm990388c. PMID 10737744.
- ↑ Hutcheson JD, Ryzhova LM, Setola V, Merryman WD (November 2012). "5-HT(2B) antagonism arrests non-canonical TGF-β1-induced valvular myofibroblast differentiation". Journal of Molecular and Cellular Cardiology. 53 (5): 707–14. doi:10.1016/j.yjmcc.2012.08.012. PMC 3472096. PMID 22940605.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.